MedTrace Logo

A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

NCT00076323 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2010-07-27

No results posted yet for this study

Summary

This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.

Conditions

  • Glucosephosphate Dehydrogenase Deficiency
  • Favism

Interventions

DRUG

Primaquine

Sponsors & Collaborators

  • Walter Reed Army Institute of Research (WRAIR)

    lead FED

Principal Investigators

  • Shon A Remich · WRAIR, Experimental Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-12-31
Completion
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00076323 on ClinicalTrials.gov